NASDAQ:REGN - Regeneron Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$294.88 -0.43 (-0.15 %)
(As of 05/24/2018 03:18 PM ET)
Previous Close$295.02
Today's Range$293.38 - $296.60
52-Week Range$281.89 - $543.55
Volume20,431 shs
Average Volume1.12 million shs
Market Capitalization$31.74 billion
P/E Ratio21.98
Dividend YieldN/A
Beta1.44

About Regeneron (NASDAQ:REGN)

Regeneron logoRegeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Debt-to-Equity Ratio0.11
Current Ratio3.59
Quick Ratio2.94

Price-To-Earnings

Trailing P/E Ratio21.98
Forward P/E Ratio17.14
P/E Growth1.06

Sales & Book Value

Annual Sales$5.87 billion
Price / Sales5.41
Cash Flow$15.8708 per share
Price / Cash18.58
Book Value$60.98 per share
Price / Book4.84

Profitability

EPS (Most Recent Fiscal Year)$13.41
Net Income$1.20 billion
Net Margins23.54%
Return on Equity29.92%
Return on Assets20.79%

Miscellaneous

Employees6,200
Outstanding Shares107,700,000

Regeneron (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron's stock symbol?

Regeneron trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron's earnings last quarter?

Regeneron (NASDAQ:REGN) released its quarterly earnings data on Thursday, May, 3rd. The biopharmaceutical company reported $4.67 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $5.08 by $0.41. The biopharmaceutical company had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.50 billion. Regeneron had a return on equity of 29.92% and a net margin of 23.54%. The business's quarterly revenue was up 14.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.92 EPS. View Regeneron's Earnings History.

When is Regeneron's next earnings date?

Regeneron is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Regeneron.

What price target have analysts set for REGN?

25 equities research analysts have issued 1 year price targets for Regeneron's stock. Their forecasts range from $290.00 to $593.00. On average, they expect Regeneron's share price to reach $428.8333 in the next year. View Analyst Ratings for Regeneron.

What are Wall Street analysts saying about Regeneron stock?

Here are some recent quotes from research analysts about Regeneron stock:
  • 1. According to Zacks Investment Research, "Regeneron’s first-quarter results were mixed with earnings beating expectations while sales missed on the same. Nevertheless, we are encouraged by the pipeline progress. The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales.  A positive outcome will boost investor sentiment as well as the company had earlier suffered setback when it decided not to advance the nesvacumab and Eylea combination study to phase III development after two phase II studies evaluating the combination therapy failed to show additional benefit over Eylea monotherapy in patients with diabetic macular edema or wet age-related macular degeneration. Any setbacks will hurt the stock as the company is heavily dependent on Eylea. Meanwhile, Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Shares have underperofrmed the industry in the last six months." (5/9/2018)
  • 2. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018)

Who are some of Regeneron's key competitors?

Who are Regeneron's key executives?

Regeneron's management team includes the folowing people:
  • Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 65)
  • Dr. George D. Yancopoulos, Pres, Chief Scientific Officer & Director (Age 58)
  • Mr. Robert E. Landry Jr., Sr. VP of Fin. & CFO (Age 54)
  • Dr. Neil Stahl Ph.D., Exec. VP of R&D (Age 61)
  • Mr. Robert J. Terifay, Exec. VP of Commercial(Leave of Absence) (Age 58)

Has Regeneron been receiving favorable news coverage?

Media coverage about REGN stock has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Regeneron earned a news sentiment score of 0.20 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.90 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Regeneron's major shareholders?

Regeneron's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.57%), Loomis Sayles & Co. L P (2.62%), Polen Capital Management LLC (1.32%), Sustainable Growth Advisers LP (0.97%), American Century Companies Inc. (0.89%) and Northern Trust Corp (0.85%). Company insiders that own Regeneron stock include Arthur F Ryan, Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron.

Which institutional investors are selling Regeneron stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, Sei Investments Co., Franklin Resources Inc., Senzar Asset Management LLC, Prudential Financial Inc., MUFG Securities EMEA plc and Swiss National Bank. Company insiders that have sold Regeneron company stock in the last year include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron.

Which institutional investors are buying Regeneron stock?

REGN stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Old Mutual Global Investors UK Ltd., Rockefeller Capital Management L.P., Summit Trail Advisors LLC, Sustainable Growth Advisers LP, American Century Companies Inc., BB Biotech AG and Natixis Advisors L.P.. View Insider Buying and Selling for Regeneron.

How do I buy shares of Regeneron?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron's stock price today?

One share of REGN stock can currently be purchased for approximately $295.1401.

How big of a company is Regeneron?

Regeneron has a market capitalization of $31.74 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron employs 6,200 workers across the globe.

How can I contact Regeneron?

Regeneron's mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron (REGN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,047 (Vote Outperform)
Underperform Votes:  858 (Vote Underperform)
Total Votes:  1,905
MarketBeat's community ratings are surveys of what our community members think about Regeneron and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Regeneron (NASDAQ:REGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
25 Wall Street analysts have issued ratings and price targets for Regeneron in the last 12 months. Their average twelve-month price target is $428.8333, suggesting that the stock has a possible upside of 45.43%. The high price target for REGN is $593.00 and the low price target for REGN is $290.00. There are currently 1 sell rating, 16 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.282.282.352.41
Ratings Breakdown: 1 Sell Rating(s)
16 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
16 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
15 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
14 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $428.8333$454.9167$457.00$476.25
Price Target Upside: 45.43% upside40.78% upside41.47% upside23.75% upside

Regeneron (NASDAQ:REGN) Consensus Price Target History

Price Target History for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ:REGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018BarclaysSet Price TargetSell$290.00LowView Rating Details
5/7/2018Royal Bank of CanadaLower Price TargetSector Perform$342.00LowView Rating Details
5/5/2018Credit Suisse GroupSet Price TargetBuy$420.00LowView Rating Details
5/4/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$400.00 ➝ $370.00LowView Rating Details
5/4/2018Canaccord GenuityLower Price TargetHold ➝ Hold$356.00 ➝ $304.00LowView Rating Details
5/4/2018Leerink SwannSet Price TargetBuy$502.00 ➝ $435.00LowView Rating Details
5/4/2018BMO Capital MarketsSet Price TargetMarket Perform ➝ Hold$398.00 ➝ $361.00LowView Rating Details
5/4/2018CowenReiterated RatingOutperform$400.00 ➝ $350.00LowView Rating Details
5/4/2018SunTrust BanksLower Price TargetHold$344.00LowView Rating Details
5/1/2018GuggenheimDowngradeBuy ➝ NeutralLowView Rating Details
4/9/2018Raymond JamesReiterated RatingOutperform ➝ Market PerformLowView Rating Details
4/9/2018UBSDowngradeOutperform ➝ Market PerformLowView Rating Details
3/13/2018BTIG ResearchReiterated RatingHoldMediumView Rating Details
3/13/2018Deutsche BankSet Price TargetHold$367.00MediumView Rating Details
2/9/2018Robert W. BairdUpgradeNeutral ➝ OutperformHighView Rating Details
2/8/2018Jefferies GroupReiterated RatingNeutral ➝ Hold$380.00HighView Rating Details
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$455.00 ➝ $457.00LowView Rating Details
1/9/2018CitigroupReiterated RatingNeutral ➝ Neutral$380.00 ➝ $388.00HighView Rating Details
12/28/2017ArgusLower Price TargetPositive ➝ Buy$540.00 ➝ $470.00LowView Rating Details
11/16/2017Evercore ISILower Price TargetOutperform$605.00 ➝ $445.00N/AView Rating Details
11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/AView Rating Details
9/27/2017OppenheimerReiterated RatingHoldLowView Rating Details
8/9/2017Goldman Sachs GroupReiterated RatingNeutral$469.00 ➝ $472.00LowView Rating Details
7/21/2017Bank of AmericaReiterated RatingBuy$589.00 ➝ $593.00LowView Rating Details
6/26/2017Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$410.00 ➝ $480.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformLowView Rating Details
1/10/2017Wells Fargo & CoReiterated RatingMarket PerformN/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 ➝ $345.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Regeneron (NASDAQ:REGN) Earnings History and Estimates Chart

Earnings by Quarter for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ:REGN) Earnings Estimates

Current Year EPS Consensus Estimate: $17.2 EPS
Next Year EPS Consensus Estimate: $17.8 EPS

Regeneron (NASDAQ REGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018$4.60N/AView Earnings Details
5/3/2018Q1 2018$5.08$4.67$1.4999 billion$1.5110 billionViewN/AView Earnings Details
2/8/2018Q4 2017$4.18$5.23$1.5048 billion$1.5820 billionViewN/AView Earnings Details
11/8/2017Q3 2017$3.83$3.99$1.4498 billion$1.5010 billionViewN/AView Earnings Details
8/3/2017Q2 2017$2.67$4.17$1.3572 billion$1.47 billionViewListenView Earnings Details
5/4/2017Q1 2017$2.50$2.92$1.2992 billion$1.3190 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.75)($0.68)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.38)($0.49)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.32)($0.17)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.34)($0.41)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.38)($0.31)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.49)($0.38)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.34)($0.46)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.23)($0.01)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.28)($0.19)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.29)($0.22)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.30)($0.40)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.32)($0.27)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.35)($0.22)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.34)($0.15)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.46)($0.19)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Regeneron (NASDAQ:REGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Regeneron (NASDAQ REGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.42%
Institutional Ownership Percentage: 66.38%
Insider Trading History for Regeneron (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron (NASDAQ:REGN)

Regeneron (NASDAQ REGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2018George L SingDirectorSell7,000$285.29$1,997,030.00127,772View SEC Filing  
3/19/2018Joseph L GoldsteinDirectorSell2,000$350.02$700,040.0014,000View SEC Filing  
3/14/2018Joseph L GoldsteinDirectorSell2,000$340.00$680,000.0014,000View SEC Filing  
2/9/2018Joseph L GoldsteinDirectorSell1,000$325.60$325,600.00View SEC Filing  
10/5/2017Michael S BrownDirectorSell1,500$475.00$712,500.00View SEC Filing  
9/29/2017Charles A BakerDirectorSell2,000$450.00$900,000.0011,000View SEC Filing  
9/6/2017Robert E LandrySVPSell663$498.60$330,571.8010,099View SEC Filing  
9/5/2017Robert E LandryCFOSell189$501.06$94,700.3410,099View SEC Filing  
8/31/2017Robert E LandrySVPSell427$493.43$210,694.619,099View SEC Filing  
8/25/2017SanofiMajor ShareholderBuy72,378$481.36$34,839,874.08View SEC Filing  
8/24/2017SanofiMajor ShareholderBuy166,415$480.93$80,033,965.95View SEC Filing  
8/23/2017Robert E LandrySVPSell468$476.45$222,978.609,099View SEC Filing  
8/22/2017P Roy VagelosChairmanSell56,213$474.48$26,671,944.24363,638View SEC Filing  
8/18/2017P Roy VagelosChairmanSell15,191$470.15$7,142,048.65329,543View SEC Filing  
8/17/2017P Roy VagelosChairmanSell1,305$470.00$613,350.00329,543View SEC Filing  
8/16/2017P Roy VagelosChairmanSell10,986$470.17$5,165,287.62329,543View SEC Filing  
8/8/2017Robert E LandrySVPSell526$472.19$248,371.949,099View SEC Filing  
6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.989,193View SEC Filing  
6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.3043,950View SEC Filing  
6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.003,000View SEC Filing  
6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.9372,043View SEC Filing  
6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.1544,245View SEC Filing  
6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.0014,000View SEC Filing  
6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.8828,477View SEC Filing  
6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50View SEC Filing  
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30414,156View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.003,000View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.001,000View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.0012,000View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.0036,500View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.0015,125View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.0015,125View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.0040,500View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.0111,381View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.0013,000View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.0016,000View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.326,866View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44500,000View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00332,880View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.4522,029View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98351,851View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28543,348View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.009,000View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.1715,441View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.009,000View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.0014,662View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.0014,662View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.0563,102View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.5863,102View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.001,000View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.1615,600View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.2020,029View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.8424,391View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.711,068,343View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.002,000View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.5069,960View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.3625,447View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.9320,742View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00112,772View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.003,000View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.8342,087View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.1665,759View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.0910,736View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.0016,644View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.004,000View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Regeneron (NASDAQ REGN) News Headlines

Source:
DateHeadline
Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' CabometyxBiotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
finance.yahoo.com - May 23 at 3:48 PM
Regeneron (REGN) PT Set at $290.00 by BarclaysRegeneron (REGN) PT Set at $290.00 by Barclays
www.americanbankingnews.com - May 23 at 12:54 PM
Is Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Balance Sheet Strong Enough To Weather A Storm?Is Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - May 22 at 3:50 PM
Regeneron (REGN) Says NEJM Published Two Positive Phase 3 Trials Showing DUPIXENT Improved Moderate-to ...Regeneron (REGN) Says NEJM Published Two Positive Phase 3 Trials Showing DUPIXENT Improved Moderate-to ...
www.streetinsider.com - May 21 at 3:43 PM
Regeneron Announces Upcoming Investor Conference PresentationRegeneron Announces Upcoming Investor Conference Presentation
finance.yahoo.com - May 18 at 11:41 AM
Regeneron and Sanofis cemiplimab shows positive effect in early-stage lung cancer studyRegeneron and Sanofi's cemiplimab shows positive effect in early-stage lung cancer study
seekingalpha.com - May 17 at 3:46 PM
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes DataAmgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
finance.yahoo.com - May 17 at 3:46 PM
Regeneron (REGN) option implied volatility into ASCORegeneron (REGN) option implied volatility into ASCO
www.streetinsider.com - May 17 at 10:34 AM
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCORegeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO
finance.yahoo.com - May 17 at 10:34 AM
Sanofi Eczema Drug Dupixent Succeeds in Adolescents StudySanofi Eczema Drug Dupixent Succeeds in Adolescents Study
finance.yahoo.com - May 16 at 3:50 PM
BRIEF-Regeneron says Phase 3 Trial Of Dupixent Met Primary EndpointsBRIEF-Regeneron says Phase 3 Trial Of Dupixent Met Primary Endpoints
www.reuters.com - May 16 at 10:55 AM
Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary EndpointsRegeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints
www.nasdaq.com - May 16 at 10:55 AM
$1.58 Billion in Sales Expected for Regeneron (REGN) This Quarter$1.58 Billion in Sales Expected for Regeneron (REGN) This Quarter
www.americanbankingnews.com - May 15 at 5:03 AM
 Brokerages Expect Regeneron (REGN) Will Announce Earnings of $4.59 Per Share Brokerages Expect Regeneron (REGN) Will Announce Earnings of $4.59 Per Share
www.americanbankingnews.com - May 13 at 1:22 AM
Insider Selling: Regeneron (REGN) Director Sells 7,000 Shares of StockInsider Selling: Regeneron (REGN) Director Sells 7,000 Shares of Stock
www.americanbankingnews.com - May 11 at 4:21 PM
US STOCKS ON THE MOVE-Symantec, Regeneron, News Corp, Verizon, DropboxUS STOCKS ON THE MOVE-Symantec, Regeneron, News Corp, Verizon, Dropbox
www.nasdaq.com - May 11 at 3:58 PM
Regeneron Downtrend Ending But No Rush to BuyRegeneron Downtrend Ending But No Rush to Buy
finance.yahoo.com - May 11 at 3:58 PM
Regeneron: Initiating At These LevelsRegeneron: Initiating At These Levels
seekingalpha.com - May 11 at 11:28 AM
Analysts’ Recommendations for Regeneron Pharmaceuticals in MayAnalysts’ Recommendations for Regeneron Pharmaceuticals in May
finance.yahoo.com - May 10 at 10:37 AM
Regeneron (REGN) Cut to "Sell" at Zacks Investment ResearchRegeneron (REGN) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:47 PM
Regenerons Earnings Jump 92% and Yet Stock SlumpsRegeneron's Earnings Jump 92% and Yet Stock Slumps
www.baystreet.ca - May 9 at 3:50 PM
How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?
finance.yahoo.com - May 9 at 3:50 PM
How Did Regeneron Pharmaceuticals Perform in 1Q18?How Did Regeneron Pharmaceuticals Perform in 1Q18?
finance.yahoo.com - May 9 at 10:22 AM
Regeneron (REGN) Downgraded by BidaskClubRegeneron (REGN) Downgraded by BidaskClub
www.americanbankingnews.com - May 9 at 8:52 AM
Piper Jaffray Survey Shows Regenerons (REGN) Inventory Drawdown Was Not An Inflection PointPiper Jaffray Survey Shows Regeneron's (REGN) Inventory Drawdown Was Not An Inflection Point
www.streetinsider.com - May 8 at 10:11 AM
Oversold Conditions For Regeneron Pharmaceuticals (REGN)Oversold Conditions For Regeneron Pharmaceuticals (REGN)
www.nasdaq.com - May 8 at 10:11 AM
Geisinger to offer DNA sequencing to all its patientsGeisinger to offer DNA sequencing to all its patients
finance.yahoo.com - May 7 at 3:50 PM
Regeneron (REGN) Given New $342.00 Price Target at Royal Bank of CanadaRegeneron (REGN) Given New $342.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - May 7 at 2:58 PM
Why Regeneron Has 30 Percent UpsideWhy Regeneron Has 30 Percent Upside
seekingalpha.com - May 7 at 10:27 AM
Credit Suisse Group Reiterates $420.00 Price Target for Regeneron (REGN)Credit Suisse Group Reiterates $420.00 Price Target for Regeneron (REGN)
www.americanbankingnews.com - May 6 at 12:01 PM
3 Reasons Regeneron Stock Could Start Climbing Again3 Reasons Regeneron Stock Could Start Climbing Again
finance.yahoo.com - May 6 at 10:22 AM
2 Beaten-Down Biotech Stocks That Look Like Bargains Now2 Beaten-Down Biotech Stocks That Look Like Bargains Now
finance.yahoo.com - May 5 at 10:28 AM
Regeneron (REGN) Price Target Lowered to $304.00 at Canaccord GenuityRegeneron (REGN) Price Target Lowered to $304.00 at Canaccord Genuity
www.americanbankingnews.com - May 5 at 1:07 AM
Regeneron (REGN) Receives "Outperform" Rating from Leerink SwannRegeneron (REGN) Receives "Outperform" Rating from Leerink Swann
www.americanbankingnews.com - May 5 at 12:55 AM
Barclays Analysts Give Regeneron (REGN) a $290.00 Price TargetBarclays Analysts Give Regeneron (REGN) a $290.00 Price Target
www.americanbankingnews.com - May 4 at 10:31 PM
Regeneron (REGN) Given Hold Rating at BMO Capital MarketsRegeneron (REGN) Given Hold Rating at BMO Capital Markets
www.americanbankingnews.com - May 4 at 5:47 PM
Regeneron (REGN) Given New $344.00 Price Target at SunTrust BanksRegeneron (REGN) Given New $344.00 Price Target at SunTrust Banks
www.americanbankingnews.com - May 4 at 5:47 PM
Regeneron (REGN) Earns "Outperform" Rating from CowenRegeneron (REGN) Earns "Outperform" Rating from Cowen
www.americanbankingnews.com - May 4 at 5:47 PM
Regenerons newer drugs disappoint, shares slipRegeneron's newer drugs disappoint, shares slip
www.reuters.com - May 4 at 3:51 PM
Regeneron (REGN) Price Target Cut to $370.00 by Analysts at Morgan StanleyRegeneron (REGN) Price Target Cut to $370.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - May 4 at 3:51 PM
Edited Transcript of REGN earnings conference call or presentation 3-May-18 12:30pm GMTEdited Transcript of REGN earnings conference call or presentation 3-May-18 12:30pm GMT
finance.yahoo.com - May 4 at 10:09 AM
Regeneron (REGN) Announces Quarterly  Earnings Results, Beats Estimates By $0.50 EPSRegeneron (REGN) Announces Quarterly Earnings Results, Beats Estimates By $0.50 EPS
www.americanbankingnews.com - May 3 at 8:12 PM
Form 8-K REGENERON PHARMACEUTICAL For: May 03Form 8-K REGENERON PHARMACEUTICAL For: May 03
www.streetinsider.com - May 3 at 3:46 PM
Cigna, Regeneron, New York Times and Ferrari post earnings beatsCigna, Regeneron, New York Times and Ferrari post earnings beats
finance.yahoo.com - May 3 at 3:46 PM
Sanofi/Regenerons Dupixent, the Darling of Atopic DermatitisSanofi/Regeneron's Dupixent, the Darling of Atopic Dermatitis
www.prnewswire.com - May 3 at 3:46 PM
Regeneron Isnt Changing, for Better or WorseRegeneron Isn't Changing, for Better or Worse
www.bloomberg.com - May 3 at 3:46 PM
Regeneron Isn’t Changing, for Better or WorseRegeneron Isn’t Changing, for Better or Worse
finance.yahoo.com - May 3 at 3:46 PM
Health Secretary Alex Azar: ‘Bold action is on the way’ for drug pricesHealth Secretary Alex Azar: ‘Bold action is on the way’ for drug prices
finance.yahoo.com - May 3 at 3:46 PM
BRIEF-Regeneron Reports Q1 GAAP Earnings Per Share $4.16BRIEF-Regeneron Reports Q1 GAAP Earnings Per Share $4.16
www.reuters.com - May 3 at 10:08 AM
Regeneron Reports First Quarter 2018 Financial and Operating ResultsRegeneron Reports First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 3 at 10:08 AM

SEC Filings

Regeneron (NASDAQ:REGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Regeneron (NASDAQ:REGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Regeneron (NASDAQ REGN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.